Evidence map›Paper›PMID 25867857›Full record

ArticleNanomedicine (London, England)2015

Enhancement of anti-tumor effect of particulate vaccine delivery system by 'bacteriomimetic' CpG functionalization of poly-lactic-co-glycolic acid nanoparticles.

Rutika A Kokate, Sanjay I Thamake, Pankaj Chaudhary, Brittney Mott, Sangram Raut, Jamboor K Vishwanatha, Harlan P Jones

Erratum issuedAbstract read
In one paragraph

Article in Nanomedicine (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Surgical Primary Tumor Resection Reduces Accumulation of CD11bPharmaceuticals (Basel, Switzerland) · 2023
    Article
  3. Article
  4. Article
  5. CpG-Based Nanovaccines for Cancer Immunotherapy.International journal of nanomedicine · 2021
    Review
  6. Polymeric Nanoparticle-Based Vaccine Adjuvants and Delivery Vehicles.Current topics in microbiology and immunology · 2021
    Review
  7. Fluorescence properties of doxorubicin in PBS buffer and PVA films.Journal of photochemistry and photobiology. B, Biology · 2017
    Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Rutika A KokateDepartment of Molecular & Medical Genetics, University of North Texas Health Science Center (UNTHSC), Fort Worth, TX 76107, USA.
Sanjay I Thamake
Pankaj Chaudhary
Brittney Mott
Sangram Raut
Jamboor K Vishwanatha
Harlan P Jones

Funding

Triple Negative Breast Cancer: Novel Biomarkers and Therapeutic StrategiesP20MD006882 · NIMHD · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI GHORPADE, ANUJA · 2012 to 2016
$5.8M
NIMHD NIH HHS 1P20 MD006882NIMHD NIH HHS P20 MD006882
6 · The paper itself

Abstract

aimLow immunogenicity remains a major obstacle in realizing the full potential of cancer vaccines. In this study, we evaluated CpG-coated tumor antigen (Tag)-encapsulating 'bacteriomimetic' nanoparticles (CpG-nanoparticle [NP]-Tag NPs) as an approach to enhance anti-tumor immunity. MATERIALS &

methodsCpG-NP-Tag NPs were synthesized, characterized for their physicochemical properties and tested in vivo.

resultsWe found CpG predosing followed by intraperitoneal (IP) immunization with CpG-NP-Tag NPs significantly attenuated tumor growth in female BALB/c mice compared with respective controls. Histopathological and Immunofluorescence data revealed CpG-NP-Tag tumors had lower proliferation, higher apoptotic activity, greater CD4(+) and CD8(+) T cell infiltration as well as higher IFN-γ levels as compared with control groups.

conclusionOur findings suggest CpG-NP-Tag NPs can enhance anti-tumor effect of nanoparticulate tumor vaccination system.

Indexed as

AnimalsAntigens, NeoplasmAntineoplastic AgentsApoptosisCancer VaccinesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell Line, TumorCell ProliferationCpG IslandsDrug Delivery SystemsFemaleInterferon-gammaKi-67 AntigenLactic AcidLuminescenceAntigens, NeoplasmAntineoplastic AgentsCancer VaccinesInterferon-gammaKi-67 AntigenLactic AcidPolyglycolic AcidPolylactic Acid-Polyglycolic Acid Copolymerantigenbreast cancerimmunotherapynanoparticleNPvaccines

Identifiers

PMID25867857
PMCPMC4839968

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.